Carlos Pérez Muguía, CEO at NYCE, showcases the increasing added value brought by this leading Cofepris’ authorized third party (ATP) to the healthcare industry, the future objectives of the company to enter into the biotech field, and its readiness to continue helping Cofepris in other areas to further strengthen Mexico’s healthcare eco-system.
Could you please introduce to our international readers the key operations of NYCE as well as the company’s milestones during the last five years?
"Our mix of revenues of pharmaceutical versus medical devices has varied throughout the last three years, hand in hand with the performance of each industry."
